Pipeline
Code name | Generic Name | Therapeutic area (Major indications) |
Development stage | Status | ||||
---|---|---|---|---|---|---|---|---|
Pre-clinical | Phase 1 | Phase 3 | Application | Approval | ||||
FKB327 | Adalimumab (fully human anti-TNF-α monoclonal antibody) |
Immunology (Rheumatoid arthritis, Plaque psoriasis, Crohn's disease) |
![]() |
|
||||
FKB238 | Bevacizumab (humanized anti-VEGF monoclonal antibody) |
Oncology (Colorectal cancer, Non-small cell lung cancer, Cervical cancer) |
![]() |
Phase 3 global clinical stages in non-small cell lung cancer |